N/A N=64 Randomized Single-blind Treatment

Cognitive Rehabilitation in Post-COVID-19 Syndrome

Post-COVID-19 Syndrome

Bottom Line

View on ClinicalTrials.gov: NCT06136871 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Mar 2026

Primary outcome: Primary: Recruitment Rate — 65 Participants

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: CO-OP Procedures (Behavioral); Inactive Control Group (Behavioral)
Age: Adult · 18+ yrs
Sex: All
Sponsor: University of Missouri-Columbia
Primary completion: Jun 2025

Outcome Measures

Outcome	Result	p-value
PRIMARY Recruitment Rate	65	—
PRIMARY Retention Rate	21; 27	—
PRIMARY Telehealth Usability Questionnaire (TUQ)	5.834; 5.688	—
PRIMARY Acceptability of Intervention Measure (AIM)	4.381; 2.676	—
PRIMARY Intervention Appropriateness Measure (IAM)	4.29; 2.29	—
PRIMARY Feasibility of Intervention Measure (FIM)	4.55; 3.69	—
PRIMARY Canadian Occupational Performance Measure (COPM) Performance, Trained Goals	4.343; 3.833; 6.745; 4.685	—
PRIMARY Canadian Occupational Performance Measure (COPM) Satisfaction, Trained Goals	3.198; 2.787; 7.014; 4.556	—
SECONDARY Delis-Kaplan Executive Function System (DKEFS)- Color-Word Interference, Age-Corrected Time	10.000; 9.963; 10.952; 11.074	—
SECONDARY Delis-Kaplan Executive Function System (DKEFS)- Color-Word Interference, Age-Corrected Errors	11.429; 10.704; 11.667; 11.148	—
SECONDARY Patient-Reported Outcomes Measurement Information System (PROMIS) Cognitive Function	35.486; 33.844; 38.343; 36.930	—
SECONDARY Cambridge Neuropsychological Test Automated Battery (CANTAB) Rapid Visual Information Processing Subtest	0.339; 0.394; 0.742; 0.707	—
SECONDARY CANTAB Spatial Working Memory Subtest	0.588; 0.263; 1.080; 0.744	—
SECONDARY CANTAB Stockings of Cambridge Subtest	0.403; 0.538; 0.522; 0.755	—
SECONDARY CANTAB Delayed Matching to Sample Subtest	-0.269; -0.415; 0.004; 0.065	—
SECONDARY CANTAB Paired Associates Learning Subtest	0.736; 0.354; 0.308; 0.532	—
SECONDARY Canadian Occupational Performance Measure (COPM) Performance, Untrained Goals	3.667; 4.259; 5.476; 4.889	—
SECONDARY Canadian Occupational Performance Measure (COPM) Satisfaction, Untrained Goals	3.524; 3.259; 5.905; 4.407	—
SECONDARY World Health Organization Quality of Life Assessment Instrument (WHOQOL-100) - Physical Domain	35.813; 38.812; 38.492; 39.660	—
SECONDARY World Health Organization Quality of Life Assessment Instrument (WHOQOL-100) - Social Domain	58.662; 65.500; 63.333; 67.067	—
SECONDARY World Health Organization Quality of Life Assessment Instrument (WHOQOL-100) - Environmental Domain	61.719; 65.595; 66.927; 66.435	—
SECONDARY World Health Organization Quality of Life Assessment Instrument (WHOQOL-100) - Spiritual Domain	62.202; 63.194; 65.476; 61.806	—
SECONDARY World Health Organization Quality of Life Assessment Instrument (WHOQOL-100) - Independence Domain	41.094; 38.161; 45.685; 41.030	—
SECONDARY World Health Organization Quality of Life Assessment Instrument (WHOQOL-100) - Psychological Domain	50.595; 52.019; 57.500; 53.472	—
SECONDARY Cognitive Failures Questionnaires Total Score	58.667; 60.889; 54.143; 57.889	—

Summary

The first aim of this study is to determine the feasibility of delivering CO-OP remotely to individuals experiencing cognitive impairments that limit everyday activities in post-COVID-19 syndrome (PCS). The second aim of this study is to assess the effect of CO-OP on activity performance, subjective and objective cognition, and quality of life in a sample of individuals with PCS. The research team hypothesizes that effect size estimations will indicate that CO-OP will have a greater positive effect, compared to an inactive control group, on activity performance, subjective and objective cognition, and quality of life in a sample of individuals who self-report PCS and cognitive impairment.

Eligibility Criteria

Inclusion Criteria

self-reported cognitive symptoms persisting for at least 6 weeks following COVID-19 infection (Cognitive Failures Questionnaire (CFQ) score >43)
self-identified activity performance goals per the Canadian Occupational Performance Measure (COPM)
documented prior diagnosis of COVID-19
read, write, and speak English fluently
ability to provide valid informed electronic consent

Exclusion Criteria

diagnosis of severe neurological or psychiatric condition(s)
dementia symptoms as indicated by a score of 21 on the Patient Health Questionnaire-9)

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT06136871). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.